Harvest One CEO Grant Froese last month said that the company’s retail strategy would be announced in “the coming weeks, after subsidiary United Greeneries penned a deal to supply its Royal Highbranded cannabis to the Ontario government.
Children with treatment-resistant epilepsy saw an 82% reduction in monthly seizures while taking – alongside their regular medications – Satipharm’s CBD capsule.
The results of the clinical trial compared favourably to those published by GW Pharmaceuticals in its ground-breaking study, said Satipharm’s principal investigator Prof. Uri Kramer, director of Pediatric Epilepsy Service at Tel Aviv Sourasky Medical Center.
GW has already received FDA approval for its CBD drug Epidiolex and expects it to be on the market by the end of 2018.
The study was conducted by Israeli-based PhytoTech Therapeutics
Harvest One is to acquire PhytoTech Limited, pending TSXV approval. approval and MMJ shareholder approval on September 28.